Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Arcutis Biotherapeutics financing should please investors, says Mizuho » 06:44
12/27/21
12/27
06:44
12/27/21
06:44
ARQT

Arcutis Biotherapeutics

$20.21 /

+1.715 (+9.28%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics already had a strong balance sheet and the additional $225M term loan facility announced on Thursday puts the company in an even stronger cash position as it transitions to commercial-stage with the potential launch of roflumilast cream in plaque psoriasis in the second half of 2022, Mizuho analyst Uy Ear tells investors in a research note. The analyst believes the stronger balance sheet provides Arcutis greater flexibility in considering future financing options. Investors "should be pleased that this raise does not dilute the existing shareholder base," says Ear, who keeps a Buy rating on the shares with a $58 price target.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$20.21 /

+1.715 (+9.28%)

ARQT Arcutis Biotherapeutics
$20.21 /

+1.715 (+9.28%)

11/24/21 Mizuho
Arcutis recent selloff a buying opportunity, says Mizuho
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
ARQT Arcutis Biotherapeutics
$20.21 /

+1.715 (+9.28%)

  • 03
    Feb
Hot Stocks
Arcutis Biotherapeutics secures $225M in non-dilutive debt financing » 08:10
12/23/21
12/23
08:10
12/23/21
08:10
ARQT

Arcutis Biotherapeutics

$18.54 /

+0.83 (+4.69%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced that it has obtained a $225M term loan facility from funds managed by SLR Capital Partners. This additional capital further strengthens Arcutis' balance sheet in advance of a potential 2022 Food and Drug Administration approval and launch of topical roflumilast cream in plaque psoriasis, and in advance of three 2022 pivotal clinical data readouts in atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. This non-dilutive financing commitment extends the Company's cash runway into 2024. Under the terms of this loan facility, $75M was drawn at closing, and an additional $125 million becomes available upon FDA approval of roflumilast cream for the treatment of plaque psoriasis. An additional $25M is also available if certain revenue milestones are achieved. The loan facility maturity date is January 2027, with the interest-only period extending for the entire five years. The loan facility is secured by the Company's assets.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$18.54 /

+0.83 (+4.69%)

ARQT Arcutis Biotherapeutics
$18.54 /

+0.83 (+4.69%)

11/24/21 Mizuho
Arcutis recent selloff a buying opportunity, says Mizuho
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
ARQT Arcutis Biotherapeutics
$18.54 /

+0.83 (+4.69%)

  • 03
    Feb
Hot Stocks
FDA accepts Arcutis Biotherapeutics' NDA for roflumilast for psoriasis » 16:10
12/22/21
12/22
16:10
12/22/21
16:10
ARQT

Arcutis Biotherapeutics

$18.50 /

+0.79 (+4.46%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced the U.S. Food and Drug Administration's acceptance for review of the company's new drug application for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act target action date of July 29. "With the FDA commencing a review of our NDA filing, we move one step closer to potentially providing a new topical treatment to the millions of Americans living with plaque psoriasis who have limited options beyond steroidal treatments," said Frank Watanabe, President and CEO of Arcutis. "We are proud to be addressing some of the most persistent medical challenges for individuals with serious skin disease and have assembled a strong team that is preparing to commercialize our first product, roflumilast cream, once approved. We look forward to working closely with the FDA during the review process." Roflumilast cream is a once-daily topical formulation of roflumilast, a highly potent and selective inhibitor of phosphodiesterase type 4, an enzyme that drives overactive immune responses. PDE4 is an established target in dermatology.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$18.50 /

+0.79 (+4.46%)

ARQT Arcutis Biotherapeutics
$18.50 /

+0.79 (+4.46%)

11/24/21 Mizuho
Arcutis recent selloff a buying opportunity, says Mizuho
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
ARQT Arcutis Biotherapeutics
$18.50 /

+0.79 (+4.46%)

  • 03
    Feb
Over a month ago
Hot Stocks
Arcutis appoints Mas Matsuda as General Counsel, Corporate Secretary » 08:03
12/16/21
12/16
08:03
12/16/21
08:03
ARQT

Arcutis Biotherapeutics

$16.01 /

+1.045 (+6.99%)

, HALO

Halozyme

$36.93 /

+2.28 (+6.58%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics (ARQT) announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary.. Matsuda joins Arcutis from Halozyme Therapeutics (HALO) and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company.

ShowHide Related Items >><<
HALO Halozyme
$36.93 /

+2.28 (+6.58%)

ARQT Arcutis Biotherapeutics
$16.01 /

+1.045 (+6.99%)

ARQT Arcutis Biotherapeutics
$16.01 /

+1.045 (+6.99%)

11/24/21 Mizuho
Arcutis recent selloff a buying opportunity, says Mizuho
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
HALO Halozyme
$36.93 /

+2.28 (+6.58%)

12/02/21 Canaccord
Halozyme price target raised to $48 from $27 at Canaccord
06/14/21
Fly Intel: Top five analyst initiations
06/14/21 Evercore ISI
Halozyme initiated with an Outperform at Evercore ISI
06/11/21 BMO Capital
Halozyme coverage transferred at BMO Capital
HALO Halozyme
$36.93 /

+2.28 (+6.58%)

ARQT Arcutis Biotherapeutics
$16.01 /

+1.045 (+6.99%)

  • 03
    Feb
HALO Halozyme
$36.93 /

+2.28 (+6.58%)

Hot Stocks
Arcutis announces data comparing roflumilast, commercial ceramide cream » 10:00
12/13/21
12/13
10:00
12/13/21
10:00
ARQT

Arcutis Biotherapeutics

$15.47 /

+0.12 (+0.78%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced data suggesting that Arcutis' proprietary cream vehicle had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema. The data from the two groups were similar across patient and healthcare provider assessments of tolerability and aesthetic improvement. Data from the 40-patient, single-site, randomized, double-blinded intraindividual study were presented at the annual RAD Conference. Patients with mild asteatotic eczema applied either roflumilast vehicle cream or the ceramide-containing moisturizer to their lower legs. There was no statistically significant change from baseline in TEWL at Day 15 with either preparation, suggesting that no skin barrier damage was caused by either the vehicle or the moisturizer. Patients rated the Arcutis cream vehicle positively and as comparable to the ceramide-containing moisturizer. Specifically, the study found similar improvements in dryness, redness, roughness, tightness, irritation, moisturization, smoothness and overall skin appearance between the two products.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$15.47 /

+0.12 (+0.78%)

ARQT Arcutis Biotherapeutics
$15.47 /

+0.12 (+0.78%)

11/24/21 Mizuho
Arcutis recent selloff a buying opportunity, says Mizuho
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
ARQT Arcutis Biotherapeutics
$15.47 /

+0.12 (+0.78%)

  • 03
    Feb
Recommendations
Arcutis recent selloff a buying opportunity, says Mizuho » 06:49
11/24/21
11/24
06:49
11/24/21
06:49
ARQT

Arcutis Biotherapeutics

$17.54 /

+0.56 (+3.30%)

Mizuho analyst Uy Ear…

Mizuho analyst Uy Ear sees a buying opportunity for Arcutis Biotherapeutics at current levels. The company is trading below its initial public offering price of $17 "even though the stock's fundamentals have improved significantly," Ear tells investors in a research note. The analyst management has demonstrated a track record of execution, delivering on multiple positive studies and the submission of its first new drug application in plaque psoriasis. Ear believes at current share levels the recent selloff is overdone and keeps a Buy rating on Arcutis with a $58 price target.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$17.54 /

+0.56 (+3.30%)

ARQT Arcutis Biotherapeutics
$17.54 /

+0.56 (+3.30%)

11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
05/27/21 Morgan Stanley
Arcutis Biotherapeutics initiated with an Overweight at Morgan Stanley
ARQT Arcutis Biotherapeutics
$17.54 /

+0.56 (+3.30%)

  • 03
    Feb
Initiation
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley » 06:51
11/19/21
11/19
06:51
11/19/21
06:51
ARQT

Arcutis Biotherapeutics

$18.85 /

-0.56 (-2.89%)

As previously reported,…

As previously reported, Morgan Stanley analyst Vikram Purohit assumed coverage of Arcutis Biotherapeutics with an Overweight rating with a price target of $35, down from $50. Ahead of what he calls a "catalyst-rich" second half of 2022, Purohit believes the risk/reward is "skewed to the upside," but he notes that shares have faced significant pressure recently, which he suspects is due to investor skepticism regarding the commercial potential for branded dermatology therapies as well as a lack of near-term catalysts.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$18.85 /

-0.56 (-2.89%)

ARQT Arcutis Biotherapeutics
$18.85 /

-0.56 (-2.89%)

11/19/21 Morgan Stanley
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
05/27/21 Morgan Stanley
Arcutis Biotherapeutics initiated with an Overweight at Morgan Stanley
02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
ARQT Arcutis Biotherapeutics
$18.85 /

-0.56 (-2.89%)

  • 03
    Feb
Initiation
Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley » 06:14
11/19/21
11/19
06:14
11/19/21
06:14
ARQT

Arcutis Biotherapeutics

$18.85 /

-0.56 (-2.89%)

Morgan Stanley analyst…

Morgan Stanley analyst Vikram Purohit assumed coverage of Arcutis Biotherapeutics with an Overweight rating and $35 price target.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$18.85 /

-0.56 (-2.89%)

ARQT Arcutis Biotherapeutics
$18.85 /

-0.56 (-2.89%)

06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
05/27/21 Morgan Stanley
Arcutis Biotherapeutics initiated with an Overweight at Morgan Stanley
02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
ARQT Arcutis Biotherapeutics
$18.85 /

-0.56 (-2.89%)

  • 03
    Feb
Over a quarter ago
Conference/Events
Arcutis Biotherapeutics management to meet virtually with Mizuho » 04:55
10/14/21
10/14
04:55
10/14/21
04:55
ARQT

Arcutis Biotherapeutics

$22.55 /

+0.35 (+1.58%)

Virtual Meeting to be…

Virtual Meeting to be held on October 14 hosted by Mizuho.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$22.55 /

+0.35 (+1.58%)

ARQT Arcutis Biotherapeutics
$22.55 /

+0.35 (+1.58%)

06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
05/27/21 Morgan Stanley
Arcutis Biotherapeutics initiated with an Overweight at Morgan Stanley
02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
ARQT Arcutis Biotherapeutics
$22.55 /

+0.35 (+1.58%)

  • 03
    Feb
Conference/Events
Arcutis Biotherapeutics management to meet virtually with » 13:11
10/11/21
10/11
13:11
10/11/21
13:11
ARQT

Arcutis Biotherapeutics

$22.02 /

-0.31 (-1.39%)

Virtual Meeting to be…

Virtual Meeting to be held

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$22.02 /

-0.31 (-1.39%)

ARQT Arcutis Biotherapeutics
$22.02 /

-0.31 (-1.39%)

06/29/21 Mizuho
Arcutis Biotherapeutics initiated with a Buy at Mizuho
05/27/21 Morgan Stanley
Arcutis Biotherapeutics initiated with an Overweight at Morgan Stanley
02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
ARQT Arcutis Biotherapeutics
$22.02 /

-0.31 (-1.39%)

  • 03
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.